EG
`
`—_EXHlBlT.
`WITNESS:____
`
`DATE:
`
`Anrae Wimberley, CSR 7778
`
`Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award
`
`November 22, 2019
`
`TARRYTOWN, N.Y., Nov. 22, 2019/PRNewswjre/--
`
`Columbia's highest honor bestowed for Yancopoulos' contributions to science and medicine
`
`Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that George D. Yancopoulos, M.D., Ph.D., Co-Founder, President and Chief
`Scientific Officer, was awarded Columbia College's Alexander Hamilton Medal, the highest honor awarded to a member of the Columbia College
`community for distinguished service and accomplishment in any field of endeavor.
`
`"George is a generational talent as a life scientist, technology innovator and drug developer. His abilities as a biotech leader, combined with his
`remarkably synergistic and long-term partnership with Len Schleifer, are the major drivers behind Regeneron's extraordinary growth and contributions
`to human health over the years," said Nobel Prize winner and Regeneron board member Michael S. Brown, M.D., Distinguished Chair in Biomedical
`Sciences and Regental Professor of Molecular Genetics and Internal Medicine at the University of Texas Southwestern Medical Center.
`
`Biography & Career Accomplishments
`
`Yancopoulos, the son of Greek immigrants and a life-long New Yorker, attended New York City public schools and graduated as valedictorian of the
`Bronx High School of Science, where he was a top winner of the nation's premier high school science competition, then known as the Westinghouse
`Science Talent Search. He became valedictorian of Columbia College in 1980, where he received the Eisenhower award as the school's top scholar-
`athlete while serving as captain of the crew team. Yancopoulos then received his M.D. from Columbia University's College of Physicians and Surgeons
`and his Ph.D. in Biochemistry and Molecular Biophysics from Columbia University's Graduate School of Arts and Sciences, where he was chosen to
`represent his doctoral class as commencement speaker. He launched his career as an academic scientist with Frederick W. Alt at Columbia,
`publishing seminal papers in molecular immunology.
`
`In 1989, Yancopoulos left academia to join Leonard S. Schleifer, M.D., Ph.D., his Co-founder, President and Chief Executive Officer of Regeneron.
`Under their leadership, Regeneron has become one of the most admired and innovative companies in biotech, with seven FDA-approved medicines
`since 2008, and a pipeline of over twenty additional investigational products - all homegrown in the company's own laboratories. In the last twenty
`years, fewer than 100 biotech companies have invented and successfully obtained FDA approval for even one drug, and only a handful have done this
`four or more times. Regeneron medicines include the blockbusters EYLEA® (aflibercept) Injection and Dupixent® (dupilumab). Regeneron medicines
`are used to treat vision loss, asthma, atopic dermatitis, heart disease, arthritis and cancer, and the National Institutes of Health recently announced the
`effectiveness of Regeneron's investigational Ebola virus infection therapy.
`
`Yancopoulos takes an unusually hands-on approach to drug discovery, serving as lead inventor and developer. He works closely with key members of
`his team to invent Regeneron's medicines and their underlying foundational technologies, such as the VelociGene® "knockout" platform, the
`Velocimmune® human antibody mouse, and the Veloci-Bi TMbispeciflc antibody creation platform. During the 1990s, he was among the ten most highly
`cited scientists in the world, with landmark publications pertaining to the cloning and biology of numerous growth factors and their receptors (from the
`Neurotrophins, Angiopoietins, and Ephrins to the CNTF receptor and the Agrin receptor, MUSK), on the elucidation of the mechanism of action of the
`cytokine class of receptors, and other findings leading to the development of Regeneron's medicines and technologies. His team continues to pursue
`cutting-edge research, such as through the Regeneron Genetics Center, a world-leading effort that has sequenced the exomes of nearly one million
`people and paired this information with de-identified medical records in the quest to identify new and improved treatment options.
`
`Yancopoulos is passionate about giving back to the Columbia community and committed to supporting the next generation of great young scientists.
`He leads Regeneron's numerous STEM education and mentorship programs, including a $100 million commitment to the Regeneron Science Talent
`Search, which was formerly sponsored by Intel and Westinghouse.
`
`Yancopoulos was inducted into the National Academy of Sciences in 2004 and into the Biotech Hall of Fame in 2014. He and Schleifer were selected
`as Ernst & Young's "Entrepreneurs of the Year" in 2016. Other accolades from Columbia include the Steven's Triennial Prize for original medical
`research, the University Medal of Excellence and the John Jay Award for distinguished professional achievement. Yancopoulos' efforts have also been
`recognized at the company level, as Regeneron has routinely been listed by Forbes as one of the "Ten Most Innovative Companies in the World" and
`by Science magazine as either the 1st or 2nd Top Biopharma Company to work for over the past nine years.
`
`Many of Yancopoulos' fellow R&D leaders at Regeneron also have Columbia roots, including Drew Murphy, Ph.D. (Executive Vice President,
`Research), and Lynn MacDonald, Ph.D. (Vice President, Research), who are Yancopoulos' co-inventors of the VelociGene and Velocimmune
`technologies; Christos Kyratsous, Ph.D. (Vice President, Infectious Disease and Viral Vector Technologies), who spearheaded development of
`Regeneron's Ebola treatment; Ned Braunstein, M.D. (Senior Vice President, Regulatory, Pharmacovigilance and Risk Management), and David
`Weinreich, M.D. (Senior Vice President and Head of Global Clinical Development), who lead the Company's regulatory and Global Development
`efforts; Israel Lowy, M.D., Ph.D. (Senior Vice President and Head of Translational Science and Oncology), who leads Regeneron's clinical program in
`oncology; and Jay Markowitz, M.D. (Senior Vice President, Portfolio Management), who leads strategic direction.
`
`About Regeneron
`
`Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded
`and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to
`seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines
`and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases,
`
`Mylan Exhibit 1130
`Mylan v. Regeneron, IPR2021-00880
`Page 1
`
`

`

`infectious diseases, pain and rare diseases.
`
`Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies,
`including Veloclmmune® which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies,
`and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts
`in the world.
`
`For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
`
`Regeneron Media Relations
`(914) 847-3407
`di@rPgPnrnn rnn
`
`C View original content:http://wwwprnewswire comfnews-releases/regenerons-yanc000ulos-receives-columbia-co!Ieges-alexander-hamilton-award-
`3009E33506.htmj
`
`SOURCE Regeneron Pharmaceuticals, Inc.
`
`Mylan Exhibit 1130
`Mylan v. Regeneron, IPR2021-00880
`Page 2
`
`